IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

6. E. 9/30/w NE.

In re the application of:

SWAAK

Serial Number: 08/817,704

Filed: August 25, 1997

Examiner: Vander Vegt, F.

Group Art Unit: 1644

For: USE OF ERYTHROPOIETIN IN THE TREATMENT OF RHEUMATOID

ARTHRITIS

RESPONSE UNDER 37 CFR §1.116

Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

September 26, 2000

Sir:

This is a response to the Office Action mailed March 27, 2000, the due date for which has been extended three months from June 27, 2000 to September 27, 2000 with a Petition for Extension of time attached. Applicants respectfully request reconsideration of the Office Action and entry of the following amendment:

IN THE SPECIFICATION

Page 1, immediately before line 1, insert - This is a U.S. national stage application,

under 35 U.S.C. §371, of PCT/NL95/00370, which claims a priority of EP 94203205.3

filed on March 11, 1994.--

IN THE CLAIMS

Cancel claim 17 without prejudice or disclaimer.

ENTERED (0)

FIA